Fresenius Medical Care delivered a third quarter performance where organic revenue growth remained largely flat as underlying improvements were offset by significant strategic restructuring and persistent volume headwinds. The company reported a 19% decline in operating income, primarily due to €108 million in one-time costs associated with refining its China strategy, which includes exiting the peritoneal dialysis business. Consequently, management has narrowed its full-year 2026 operating income outlook to the lower end of its previous range, anticipating continued inflation and regulatory pressures in the fourth quarter.
Key Highlights
- Revenue grew 1% to €4.94 billion, slightly exceeding consensus estimates, though organic growth was minimal at 0.1%.
- U.S. Same-Market Treatment Growth declined by -1.1%, missing expectations of a -0.9% stabilization and reflecting ongoing referral conversion challenges.
- The FME25+ transformation program delivered €74 million in sustainable savings during the quarter, with a full-year 2026 savings target of €250 million.
- Adjusted operating income (excluding special items) fell 5% to €545 million, resulting in a margin of 11.0% compared to 11.7% in the prior year period.